Gottlieb, Alice B2; Armstrong, April W2; Christensen, Robin1; Garg, Amit2; Duffin, Kristina Callis2; Boehncke, Wolf-Henning2; Merola, Joseph F2; Gladman, Dafna D2; Mease, Philip J2; Swerlick, Robert A2; Rosen, Cheryl F2; Abernethy, April2
1 Parker Instituttet, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark2 unknown
a report from the GRAPPA 2013 meeting
In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.
Journal of Rheumatology, 2014, Vol 41, Issue 6, p. 1227-9